<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066776</url>
  </required_header>
  <id_info>
    <org_study_id>SHANEW_0001</org_study_id>
    <nct_id>NCT05066776</nct_id>
  </id_info>
  <brief_title>Liquid Biopsy With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules</brief_title>
  <official_title>Liquid Biopsy in Combination With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palo Alto Veterans Institute for Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palo Alto Veterans Institute for Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a liquid biopsy, a method of detecting cancer&#xD;
      from a blood draw, combined with a PET/CT scan, a type of radiological scan, is better at&#xD;
      determining whether a lung nodule is cancerous when compared to a PET/CT scan alone. A PET/CT&#xD;
      scan is already used for diagnosis of lung nodules, but its efficacy is uncertain in nodules&#xD;
      6-20 mm in size. Therefore, the PET/CT will be evaluated for its diagnostic ability in&#xD;
      lesions this size alone and in combination with a liquid biopsy. Secondarily, a machine&#xD;
      learning model will be created to see if the combination of the PET/CT imaging data and the&#xD;
      liquid biopsy data can predict the presence of cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of liquid biopsy with PET/CT to PET/CT alone for predicting lung cancer</measure>
    <time_frame>24 months</time_frame>
    <description>Determine the sensitivity and specificity of liquid biopsy and PET/CT in combination compared with PET/CT alone for predicting lung cancer for lesions 6 mm- 20 mm in size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ctDNA gene panel ability in detecting lung cancer</measure>
    <time_frame>24 months</time_frame>
    <description>Determine the sensitivity and specificity of a ctDNA gene panel in detecting lung cancer for lesions 6 mm- 200 mm in size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA methylation liquid biopsy ability in detecting lung cancer</measure>
    <time_frame>24 months</time_frame>
    <description>Determine the sensitivity and specificity of DNA methylation liquid biopsy in detecting lung cancer for lesions 6 mm- 20 mm in size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validate ML classifier for predicting lung cancer</measure>
    <time_frame>30 months</time_frame>
    <description>Validate a machine learning (ML) classifier for predicting lung cancer using imaging and clinical data.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Solitary Pulmonary Nodule</condition>
  <condition>Multiple Pulmonary Nodules</condition>
  <arm_group>
    <arm_group_label>Patients with Pulmonary Nodule</arm_group_label>
    <description>Patients at high-risk of lung cancer found to have a pulmonary nodule 6-20 mm in size.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with lung nodules found via imaging will be selected from the VA Palo Alto Health&#xD;
        Care System.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 18 years of age&#xD;
&#xD;
          -  ECOG performance status of 0,1, or 2&#xD;
&#xD;
          -  Newly discovered lung nodule with:&#xD;
&#xD;
               1. At least one solid lung nodule measuring 6 mm- 20 mm in greatest diameter&#xD;
                  detected on screening CT&#xD;
&#xD;
               2. No single lesion larger than 20 mm in greatest diameter when multiple nodules&#xD;
                  present&#xD;
&#xD;
               3. High- or intermediate-risk nodules per American College of Chest Physician (ACCP)&#xD;
                  guidelines&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior cancer of any type for the previous 3 years&#xD;
&#xD;
          -  Prior organ, bone marrow, of hematopoietic stem cell transplant&#xD;
&#xD;
          -  Contraindication to administration of [18F]FDG&#xD;
&#xD;
          -  Inability to undergo a PET/CT scan&#xD;
&#xD;
          -  Ongoing infection, either acute or subacute&#xD;
&#xD;
          -  Severe COPD or lung disease requiring home oxygen use&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajesh Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Palo Alto Health Care System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajesh Shah, MD</last_name>
    <phone>650-493-5000</phone>
    <phone_ext>65925</phone_ext>
    <email>rajesh.shah2@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Shah, MD</last_name>
      <phone>650-493-5000</phone>
      <phone_ext>65925</phone_ext>
      <email>rajesh.shah2@va.gov</email>
    </contact>
    <investigator>
      <last_name>Rajesh Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harman Paintal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Minal Vasanawala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Millie Das, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sachin Malik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin Jensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sirish Kishore, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Rigas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Gevaert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Selby, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pritam Mukherjee, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.</citation>
    <PMID>31912902</PMID>
  </reference>
  <reference>
    <citation>MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, Mehta AC, Ohno Y, Powell CA, Prokop M, Rubin GD, Schaefer-Prokop CM, Travis WD, Van Schil PE, Bankier AA. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017 Jul;284(1):228-243. doi: 10.1148/radiol.2017161659. Epub 2017 Feb 23.</citation>
    <PMID>28240562</PMID>
  </reference>
  <reference>
    <citation>Kinsinger LS, Anderson C, Kim J, Larson M, Chan SH, King HA, Rice KL, Slatore CG, Tanner NT, Pittman K, Monte RJ, McNeil RB, Grubber JM, Kelley MJ, Provenzale D, Datta SK, Sperber NS, Barnes LK, Abbott DH, Sims KJ, Whitley RL, Wu RR, Jackson GL. Implementation of Lung Cancer Screening in the Veterans Health Administration. JAMA Intern Med. 2017 Mar 1;177(3):399-406. doi: 10.1001/jamainternmed.2016.9022.</citation>
    <PMID>28135352</PMID>
  </reference>
  <reference>
    <citation>National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.</citation>
    <PMID>21714641</PMID>
  </reference>
  <reference>
    <citation>Huo J, Xu Y, Sheu T, Volk RJ, Shih YT. Complication Rates and Downstream Medical Costs Associated With Invasive Diagnostic Procedures for Lung Abnormalities in the Community Setting. JAMA Intern Med. 2019 Mar 1;179(3):324-332. doi: 10.1001/jamainternmed.2018.6277.</citation>
    <PMID>30640382</PMID>
  </reference>
  <reference>
    <citation>National Comprehensive Cancer Network. NCCN Guidelines Lung Cancer Screening Version 1.2020.</citation>
  </reference>
  <reference>
    <citation>Li S, Zhao B, Wang X, Yu J, Yan S, Lv C, Yang Y. Overestimated value of (18)F-FDG PET/CT to diagnose pulmonary nodules: Analysis of 298 patients. Clin Radiol. 2014 Aug;69(8):e352-7. doi: 10.1016/j.crad.2014.04.007. Epub 2014 May 27.</citation>
    <PMID>24877581</PMID>
  </reference>
  <reference>
    <citation>Cescon, D. W., Bratman, S. V., Chan, S. M. &amp; Siu, L. L. Circulating tumor DNA and liquid biopsy in oncology. Nat. Cancer 1, 276-290 (2020).</citation>
  </reference>
  <reference>
    <citation>Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanawala M, Kuschner W, Bethel K, Iagaru AH, Hoh C, Shrager JB, Loo BW Jr, Bazhenova L, Nieva J, Gambhir SS, Kuhn P. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. PLoS One. 2013 Jul 5;8(7):e67733. doi: 10.1371/journal.pone.0067733. Print 2013.</citation>
    <PMID>23861795</PMID>
  </reference>
  <reference>
    <citation>Odahowski CL, Zahnd WE, Eberth JM. Challenges and Opportunities for Lung Cancer Screening in Rural America. J Am Coll Radiol. 2019 Apr;16(4 Pt B):590-595. doi: 10.1016/j.jacr.2019.01.001.</citation>
    <PMID>30947892</PMID>
  </reference>
  <reference>
    <citation>Spalluto LB, Lewis JA, LaBaze S, Sandler KL, Paulson AB, Callaway-Lane C, Grogan EL, Massion PP, Roumie CL. Association of a Lung Screening Program Coordinator With Adherence to Annual CT Lung Screening at a Large Academic Institution. J Am Coll Radiol. 2020 Feb;17(2):208-215. doi: 10.1016/j.jacr.2019.08.010. Epub 2019 Sep 6.</citation>
    <PMID>31499025</PMID>
  </reference>
  <reference>
    <citation>Triplette M, Thayer JH, Pipavath SN, Crothers K. Poor Uptake of Lung Cancer Screening: Opportunities for Improvement. J Am Coll Radiol. 2019 Apr;16(4 Pt A):446-450. doi: 10.1016/j.jacr.2018.12.018. Epub 2019 Feb 15. Review.</citation>
    <PMID>30777648</PMID>
  </reference>
  <reference>
    <citation>Ruilong Z, Daohai X, Li G, Xiaohong W, Chunjie W, Lei T. Diagnostic value of 18F-FDG-PET/CT for the evaluation of solitary pulmonary nodules: a systematic review and meta-analysis. Nucl Med Commun. 2017 Jan;38(1):67-75. Review.</citation>
    <PMID>27741214</PMID>
  </reference>
  <reference>
    <citation>Tang K, Wang L, Lin J, Zheng X, Wu Y. The value of 18F-FDG PET/CT in the diagnosis of different size of solitary pulmonary nodules. Medicine (Baltimore). 2019 Mar;98(11):e14813. doi: 10.1097/MD.0000000000014813.</citation>
    <PMID>30882661</PMID>
  </reference>
  <reference>
    <citation>Constâncio V, Nunes SP, Henrique R, Jerónimo C. DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types. Cells. 2020 Mar 5;9(3). pii: E624. doi: 10.3390/cells9030624. Review.</citation>
    <PMID>32150897</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Palo Alto Veterans Institute for Research</investigator_affiliation>
    <investigator_full_name>Rajesh Shah</investigator_full_name>
    <investigator_title>Director of Interventional Radiology</investigator_title>
  </responsible_party>
  <keyword>PET-CT Scan</keyword>
  <keyword>Liquid Biopsies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
    <mesh_term>Solitary Pulmonary Nodule</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

